Skip to Main Content

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer

Conditions

Colon | Rectum

Phase I

What is the purpose of this trial?

This randomized phase 1b/2 open-label study will evaluate the efficacy of etrumadenant (AB928) treatment combinations in patients with metastatic colorectal cancer.

  • Trial with
    Arcus Biosciences, Inc.
  • Start Date
    01/12/2022
  • End Date
    09/20/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    01/13/2022
  • Study HIC
    #2000029908